China General Technology Group To Acquire Topfond Pharmaceutical
This article was originally published in PharmAsia News
State-owned Assets Supervision and Administration Commission of Zhumadian city has signed an agreement to transfer its 90 percent stake in Topfond Pharmaceutical Group to China General Technology Group, a company controlled by the central government. As Topfond Pharmaceutical Group is Topfond Pharmaceutical's majority shareholder, General Technology Group will indirectly hold 35.65 percent stake in Topfond Pharmaceutical after the equity transfer and become the biggest shareholder of the company. According to the agreement, when SASAC's share in Topfond Pharmaceutical falls below 3 percent or General Technology's fund injection reaches RMB 1 billion, SASAC will transfer all its stake in Topfond to General Technology. (Click here for more - Chinese Language)
You may also be interested in...
Russia is promising the best of both worlds – a low price with a near-perfect efficacy. While the basic science is plausible, its best-in-class claims are bound to generate skepticism.
The Belgian biotech has divested its drug discovery services unit in Croatia which was making a nice profit but was not a priority as Galapagos concentrates on setting up its commercial operations in Europe.
In the first of a two-part article on transparency provisions for the new EU clinical trial portal, the Pink Sheet reports on aspects that sponsors must consider to protect commercially confidential information in their clinical trial applications. The second article will look at the approach taken by Merck and discuss outstanding hot topics in relation to transparency and CTIS.